PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
25223561-8	2015	Therefore, MVK and FDFT1 polymorphisms are genetic determinants for BMD response to alendronate therapy in postmenopausal Chinese women.	Alendronate	84-95	mevalonate kinase	Homo sapiens	11-14	
26096667-3	2015	MKD is caused by mutations affecting the mevalonate kinase enzyme, in the cholesterol pathway and alendronate can be used to biochemically mimic the genetic defect as it inhibits farnesyl pyrophosphate synthase in the same pathway.	Alendronate	98-109	mevalonate kinase	Homo sapiens	41-58